X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs STERLING BIOTECH - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA STERLING BIOTECH SUN PHARMA/
STERLING BIOTECH
 
P/E (TTM) x 36.9 -0.3 - View Chart
P/BV x 3.9 0.0 29,164.8% View Chart
Dividend Yield % 0.3 0.0 -  

Financials

 SUN PHARMA   STERLING BIOTECH
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
STERLING BIOTECH
Dec-13
SUN PHARMA/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs70111 6,671.4%   
Low Rs4333 12,741.2%   
Sales per share (Unadj.) Rs110.426.8 411.9%  
Earnings per share (Unadj.) Rs11.0-15.0 -73.4%  
Cash flow per share (Unadj.) Rs17.2-5.5 -315.4%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs158.854.9 289.4%  
Shares outstanding (eoy) m2,399.26267.87 895.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.10.3 1,980.3%   
Avg P/E ratio x51.6-0.5 -11,112.7%  
P/CF ratio (eoy) x32.9-1.3 -2,586.1%  
Price / Book Value ratio x3.60.1 2,818.8%  
Dividend payout %18.20-   
Avg Mkt Cap Rs m1,360,0211,862 73,052.7%   
No. of employees `00017.81.4 1,313.8%   
Total wages/salary Rs m53,671547 9,815.4%   
Avg. sales/employee Rs Th14,890.95,303.3 280.8%   
Avg. wages/employee Rs Th3,017.1403.8 747.1%   
Avg. net profit/employee Rs Th1,480.6-2,959.0 -50.0%   
INCOME DATA
Net Sales Rs m264,8957,181 3,689.0%  
Other income Rs m8,38843 19,689.2%   
Total revenues Rs m273,2827,223 3,783.3%   
Gross profit Rs m56,081947 5,922.6%  
Depreciation Rs m14,9982,543 589.7%   
Interest Rs m5,1764,377 118.2%   
Profit before tax Rs m44,295-5,931 -746.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-9,5050-   
Tax Rs m8,452-1,924 -439.2%   
Profit after tax Rs m26,338-4,007 -657.4%  
Gross profit margin %21.213.2 160.5%  
Effective tax rate %19.132.4 58.8%   
Net profit margin %9.9-55.8 -17.8%  
BALANCE SHEET DATA
Current assets Rs m316,35914,335 2,206.9%   
Current liabilities Rs m198,64349,809 398.8%   
Net working cap to sales %44.4-494.0 -9.0%  
Current ratio x1.60.3 553.4%  
Inventory Days Days95403 23.5%  
Debtors Days Days108171 63.1%  
Net fixed assets Rs m213,17855,432 384.6%   
Share capital Rs m2,399268 895.6%   
"Free" reserves Rs m378,60613,935 2,716.9%   
Net worth Rs m381,00614,701 2,591.7%   
Long term debt Rs m17,7219,478 187.0%   
Total assets Rs m643,02873,988 869.1%  
Interest coverage x9.6-0.4 -2,692.8%   
Debt to equity ratio x00.6 7.2%  
Sales to assets ratio x0.40.1 424.5%   
Return on assets %4.90.5 978.4%  
Return on equity %6.9-27.3 -25.4%  
Return on capital %10.0-6.4 -156.0%  
Exports to sales %025.9 0.0%   
Imports to sales %00.2 0.0%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs mNA12 0.0%   
Fx inflow Rs m40,8161,860 2,194.7%   
Fx outflow Rs m30,14325 121,106.5%   
Net fx Rs m10,6731,835 581.7%   
CASH FLOW
From Operations Rs m39,0721,719 2,273.3%  
From Investments Rs m-33,708-3,148 1,070.7%  
From Financial Activity Rs m-15,3931,426 -1,079.4%  
Net Cashflow Rs m-7,359-3 216,444.1%  

Share Holding

Indian Promoters % 63.7 33.9 187.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 0.0 -  
FIIs % 23.0 9.9 232.3%  
ADR/GDR % 0.0 16.9 -  
Free float % 8.3 39.3 21.1%  
Shareholders   133,026 21,482 619.2%  
Pledged promoter(s) holding % 0.5 55.9 0.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   ALEMBIC LTD  SHASUN PHARMA  PFIZER  TORRENT PHARMA  PANACEA BIOTECH  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade in Red, Oil on the Boil, and Top Stocks in Action(Pre-Open)

The BSE Sensex closed lower by 53 points to end the day at 36,305. While the broader NSE Nifty ended the day down by 136 points to end at 10,975.

Related Views on News

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 19, 2018 | Updated on Sep 19, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Sep 24, 2018 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - JUBILANT LIFE SCIENCES COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS